ArticleBlood2017

Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation.

Stefan O Ciurea et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.